blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2114990

EP2114990 - Method for predicting the response of NSCLC-patients to treatment by an EGFR-TK inhibitor [Right-click to bookmark this link]
Former [2009/46]GENE AND PROTEIN EXPRESSION PROFILES ASSOCIATED WITH THE THERAPEUTIC EFFICACY OF EGFR-TK INHIBITORS
[2011/26]
StatusNo opposition filed within time limit
Status updated on  07.09.2012
Database last updated on 11.09.2024
Most recent event   Tooltip30.05.2014Lapse of the patent in a contracting state
New state(s): LU		published on 02.07.2014  [2014/27]
Applicant(s)For all designated states
Nuclea Biomarkers LLC
46 Elm Street
Pittsfield, MA 01210 / US
[N/P]
Former [2009/46]For all designated states
Nuclea Biomarkers LLC
105 South Street
Pittsfield, MA 01201 / US
Inventor(s)01 / MURACA, Patrick, J.
8A Stratford Avenue
Pittsfield, MA 01201 / US
 [2009/46]
Representative(s)Forstmeyer, Dietmar, et al
Boeters & Lieck
Oberanger 32
80331 München / DE
[N/P]
Former [2009/46]Forstmeyer, Dietmar, et al
Boeters & Lieck Oberanger 32
D-80331 München / DE
Application number, filing date08726179.827.02.2008
[2009/46]
WO2008US02602
Priority number, dateUS20070903694P27.02.2007         Original published format: US 903694 P
[2009/46]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2008106175
Date:04.09.2008
Language:EN
[2008/36]
Type: A2 Application without search report 
No.:EP2114990
Date:11.11.2009
Language:EN
The application published by WIPO in one of the EPO official languages on 04.09.2008 takes the place of the publication of the European patent application.
[2009/46]
Type: B1 Patent specification 
No.:EP2114990
Date:02.11.2011
Language:EN
[2011/44]
Type: B9 Corrected patent specification 
No.:EP2114990
Date:28.03.2012
[2012/13]
Search report(s)International search report - published on:US20.11.2008
(Supplementary) European search report - dispatched on:EP10.03.2010
ClassificationIPC:C07K14/00
[2009/46]
CPC:
G01N33/57423 (EP,US); C12Q1/6886 (EP,US); C12Q2600/106 (EP,US);
C12Q2600/118 (EP,US); G01N2333/71 (EP,US)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2009/46]
TitleGerman:Verfahren zur Vorhersage ob NSCLC-Patienten auf eine Behandlung mit einem EGFR-TK-Hemmer ansprechen[2011/26]
English:Method for predicting the response of NSCLC-patients to treatment by an EGFR-TK inhibitor[2011/26]
French:Méthode de prédiction de la réponse à un traitment par un inhibiteur de tyrosine kinase du récepteur à l'EGF des patients atteints de carcinome non à petites cellules[2011/26]
Former [2009/46]MIT DER THERAPEUTISCHEN WIRKUNG VON EGFR-TK-HEMMERN ASSOZIIERTE GEN- UND PROTEINEXPRESSIONSPROFILE
Former [2009/46]GENE AND PROTEIN EXPRESSION PROFILES ASSOCIATED WITH THE THERAPEUTIC EFFICACY OF EGFR-TK INHIBITORS
Former [2009/46]PROFILS D'EXPRESSION DE GENES ET DE PROTEINES ASSOCIES A L'EFFICACITE THERAPEUTIQUE D'INHIBITEURS EGFR-TK
Entry into regional phase26.08.2009National basic fee paid 
26.08.2009Search fee paid 
26.08.2009Designation fee(s) paid 
26.08.2009Examination fee paid 
Examination procedure26.08.2009Examination requested  [2009/46]
24.06.2010Amendment by applicant (claims and/or description)
18.07.2011Communication of intention to grant the patent
16.09.2011Fee for grant paid
16.09.2011Fee for publishing/printing paid
Divisional application(s)EP11008690.7  / EP2413142
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  18.07.2011
Opposition(s)03.08.2012No opposition filed within time limit [2012/41]
Fees paidRenewal fee
26.08.2010Renewal fee patent year 03
16.02.2011Renewal fee patent year 04
Penalty fee
Additional fee for renewal fee
28.02.201003   M06   Fee paid on   26.08.2010
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT02.11.2011
CY02.11.2011
EE02.11.2011
HR02.11.2011
LT02.11.2011
LV02.11.2011
MT02.11.2011
PL02.11.2011
RO02.11.2011
SI02.11.2011
TR02.11.2011
BG02.02.2012
GR03.02.2012
LU27.02.2012
MC29.02.2012
PT02.03.2012
[2014/27]
Former [2014/21]AT02.11.2011
CY02.11.2011
EE02.11.2011
HR02.11.2011
LT02.11.2011
LV02.11.2011
MT02.11.2011
PL02.11.2011
RO02.11.2011
SI02.11.2011
TR02.11.2011
BG02.02.2012
GR03.02.2012
MC29.02.2012
PT02.03.2012
Former [2013/35]AT02.11.2011
CY02.11.2011
EE02.11.2011
HR02.11.2011
LT02.11.2011
LV02.11.2011
MT02.11.2011
PL02.11.2011
RO02.11.2011
SI02.11.2011
BG02.02.2012
GR03.02.2012
MC29.02.2012
PT02.03.2012
Former [2013/07]AT02.11.2011
CY02.11.2011
EE02.11.2011
HR02.11.2011
LT02.11.2011
LV02.11.2011
PL02.11.2011
RO02.11.2011
SI02.11.2011
BG02.02.2012
GR03.02.2012
MC29.02.2012
PT02.03.2012
Former [2012/42]CY02.11.2011
EE02.11.2011
HR02.11.2011
LT02.11.2011
LV02.11.2011
PL02.11.2011
RO02.11.2011
SI02.11.2011
BG02.02.2012
GR03.02.2012
MC29.02.2012
PT02.03.2012
Former [2012/36]CY02.11.2011
EE02.11.2011
HR02.11.2011
LT02.11.2011
LV02.11.2011
PL02.11.2011
RO02.11.2011
SI02.11.2011
BG02.02.2012
GR03.02.2012
PT02.03.2012
Former [2012/35]CY02.11.2011
EE02.11.2011
HR02.11.2011
LT02.11.2011
LV02.11.2011
PL02.11.2011
SI02.11.2011
BG02.02.2012
GR03.02.2012
PT02.03.2012
Former [2012/28]CY02.11.2011
HR02.11.2011
LT02.11.2011
LV02.11.2011
PL02.11.2011
SI02.11.2011
GR03.02.2012
PT02.03.2012
Former [2012/27]HR02.11.2011
LT02.11.2011
LV02.11.2011
PL02.11.2011
SI02.11.2011
GR03.02.2012
PT02.03.2012
Former [2012/26]LT02.11.2011
LV02.11.2011
PL02.11.2011
SI02.11.2011
GR03.02.2012
PT02.03.2012
Former [2012/24]LT02.11.2011
LV02.11.2011
SI02.11.2011
GR03.02.2012
PT02.03.2012
Former [2012/23]LT02.11.2011
GR03.02.2012
PT02.03.2012
Former [2012/20]LT02.11.2011
Documents cited:Search[XAI]  - BALKO J M ET AL, "Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors", BMC GENOMICS, (20061110), vol. 7, no. 1, page 289, XP021022254 [X] 1 * the whole document, in particular abstract; paragraph 1 and 5 of "Discussion"; additional file 3 * [A] 4-5 [I] 2-3

DOI:   http://dx.doi.org/10.1186/1471-2164-7-289
    [ ] - BALKO J ET AL, "Additional File 3: Genes 51-180 of the EGFR TKI sensitivity expression signature", BMC Genomics, (20061110), URL: http://www.biomedcentral.com/content/supplementary/1471-2164-7-289-S3.doc, (20100118), XP002563766 [ ] * page 2, row "EGFR" *
 [A]  - HAN S-W ET AL, "Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa(R), ZD1839) in chemotherapy-resistant non-small cell lung cancer", INT J CANCER, (20050101), vol. 113, no. 1, pages 109 - 115, XP002563767 [A] 6-8 * the whole document, in particular abstract *

DOI:   http://dx.doi.org/10.1002/ijc.20550
 [A]  - CAPPUZZO F ET AL, "Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer", J NATL CANCER INST, (20040804), vol. 96, no. 15, pages 1133 - 1141, XP002563768 [A] 6-8 * the whole document, in particular abstract *

DOI:   http://dx.doi.org/10.1093/jnci/djh217
International search[X]  - MIYAKAWA et al., "Increased expression of phosphorylated p70S6 kinase and Akt in papillary thyroid cancer tissues.", Endocrine J, (20030000), vol. 50, no. 1, pages 77 - 83, XP008115300 [X] 1 * See entire document *

DOI:   http://dx.doi.org/10.1507/endocrj.50.77
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.